---
trial_id: 730
discovery_date: 2022-04-24 16:23:21.893911
date: 2022-04-24 16:23:21.893911
title: "Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)"
summary: |
  <p>EudraCT Number: 2021-000307-20<br />Sponsor Protocol Number: COMB157GDE01<br />Sponsor Name: Novartis Pharma Vertriebs GmbH <br />Start Date: 2021-04-28<br />Medical condition: relapsing multiple sclerosis <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000307-20/DE">DE</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000307-20'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2021-000307-20<br />Sponsor Protocol Number: COMB157GDE01<br />Sponsor Name: Novartis Pharma Vertriebs GmbH <br />Start Date: 2021-04-28<br />Medical condition: relapsing multiple sclerosis <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000307-20/DE">DE</a> (Ongoing)</p>